Forodesine

CHEMBL218291 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
266.2 g/mol
LogP
-2.3
Phase
4

An investigational purine nucleoside phosphorylase inhibitor that disrupts the metabolism of deoxyguanosine in lymphoid cells, leading to selective death of malignant T-cells. It has been studied for the treatment of T-cell leukemia and lymphoma. This targeted mechanism offers a potentially more selective approach compared to conventional chemotherapy.

分子量

266.2500 g/mol

LogP

-2.30

TPSA

130.00 Ų

リピンスキーの五則

適合

治療領域

作用機序

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12

InChI

InChI=1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1

Molecular Formula

C11H14N4O4

HBD / HBA

6 / 6

回転可能結合数

2

重原子数

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

An investigational purine nucleoside phosphorylase inhibitor that disrupts the metabolism of deoxyguanosine in lymphoid cells, leading to selective death of malignant T-cells. It has been studied for the treatment of T-cell leukemia and lymphoma. This targeted mechanism offers a potentially more selective approach compared to conventional chemotherapy.

Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.

Yes, Forodesine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL218291. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 135409409. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.